Compare OBAI & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OBAI | CMMB |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2M | 13.8M |
| IPO Year | 2025 | 2023 |
| Metric | OBAI | CMMB |
|---|---|---|
| Price | $0.36 | $1.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 629.2K | 61.8K |
| Earning Date | 05-27-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 40.53 | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $9,972,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $47.75 |
| Revenue Growth | ★ 2.42 | N/A |
| 52 Week Low | $0.36 | $0.88 |
| 52 Week High | $19.95 | $3.86 |
| Indicator | OBAI | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 34.24 | 62.20 |
| Support Level | N/A | $1.41 |
| Resistance Level | $0.65 | $2.21 |
| Average True Range (ATR) | 0.05 | 0.12 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 10.83 | 81.10 |
Our Bond Inc is a personal security service through its AI-powered Preventive Personal Security platform. It is trusted by corporations, cities, and universities, and has already supported many security service requests, emergencies and life-saving interventions. The cloud-based Bond Preventative Personal Security Platform provides users with remote protective services via phone app (using its Bond Preventative Personal Security Platform) and with 24/7 support from its Personal Security Agents, who are in Bond Command Centers and can respond rapidly. It offers distinct services through its phone app (the Bond App) and fully automated Bond Command Centers. Geographically, the company operates in Israel, France, and United States. It derives maximum revenue from United States.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.